Zimmer Biomet Announces Second Quarter 2025 Financial Results

Core Insights - Zimmer Biomet Holdings, Inc. reported second quarter net sales of $2.077 billion, reflecting a 7.0% increase year-over-year, with a 5.4% increase on a constant currency basis and a 2.8% increase on an organic constant currency basis [1][7][30] - The company achieved net earnings of $152.8 million for the second quarter, with diluted earnings per share at $0.77 and adjusted diluted earnings per share at $2.07, marking a 3.0% increase [2][7][27] - The company has tightened its full-year 2025 revenue growth guidance to 6.7% - 7.7% for reported revenue, 6.2% - 7.2% for constant currency revenue, and 3.5% - 4.5% for organic constant currency revenue, while increasing adjusted earnings per share guidance to $8.10 - $8.30 [7][9][32] Financial Performance - For the three months ended June 30, 2025, net sales in the United States were $1,173.8 million, up 6.1%, while international sales reached $903.5 million, up 8.1% [6][30] - The product category performance showed U.S. knees sales at $448.7 million (up 1.7%) and hips sales at $272.5 million (up 5.2%), with S.E.T. sales at $550.6 million, reflecting a significant 17.3% increase [6][30] - For the six months ended June 30, 2025, total net sales were $3,986.4 million, a 4.0% increase from the previous year, with U.S. sales at $2,287.4 million (up 3.7%) and international sales at $1,699.0 million (up 4.5%) [28][31] Strategic Developments - The company emphasized the success of its new product cycle, particularly in the U.S. hips and knees portfolios, and noted strong growth in its global S.E.T. business [4] - The recent agreement to acquire Monogram Technologies is seen as a strategic move to enhance its capabilities in surgical robotics, aligning with the company's long-term strategy focused on customer-centric innovation [4][12]